Very highly technical stuff was discussed that only you can understand Bear. You should be able to access it soon on the Bioasis home page. May be ready now.

My take: Opening up the horizon for Bioasis with new EGF assets may be a better move than sticking with the same old same old. So far the BBB approach has not produced much and the Share Price keeps on the downward spiral. Let's see if the EGF Assets improve the share price because this is what it's all about for shareholders. Let's not worry about Nasdaq and the unnamed BC broker being bandied about at Stockhouse. First thing first,...  finding the cash for the 2, Phase 2 Clinical Trials. No sense in getting ahead of ourselves in this regard.

Patent extensions for CNS therapeutics via licensing the xB3 discovery platform (transporting medicine into the brain) is what it's all about for Bioasis. But for now, this will need to wait a little while longer.

Koo